의약품 검사기 시장 : 규모, 점유율, 성장, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of pharmaceutical inspection machines Market

The global pharmaceutical inspection machines market size was valued at USD 1,022.10 million in 2025 and is projected to grow from USD 1,103.20 million in 2026 to USD 2,263.50 million by 2034, exhibiting a CAGR of 9.40% during the forecast period. Asia Pacific dominated the global market with a 37.20% share in 2025, reflecting strong pharmaceutical manufacturing expansion across emerging economies.

Pharmaceutical inspection machines are automated and semi-automated systems used in drug manufacturing to ensure product quality, packaging integrity, and regulatory compliance. These systems detect visual, dimensional, and packaging defects, verify labels and codes, and identify non-visible faults. Their adoption enhances throughput, reduces recall risks, ensures patient safety, and supports serialization and anti-counterfeit measures.

Market Dynamics

Market Drivers

Rising regulatory and quality compliance requirements are major drivers of market growth. Regulatory authorities such as the FDA and adherence to Good Manufacturing Practices (GMP) require strict validation processes for sterile manufacturing, serialization, and traceability. Advanced inspection technologies have significantly reduced drug recalls due to quality issues. Increasing pharmaceutical outsourcing in emerging regions has further strengthened the demand for standardized inspection systems across manufacturing sites.

Growing emphasis on patient safety and high-quality pharmaceutical products is compelling manufacturers to upgrade legacy inspection systems with automated and AI-enabled solutions.

Market Challenges

Despite strong growth potential, high capital expenditure (CAPEX) requirements pose a key challenge. Procurement involves lengthy Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) validation cycles, along with regulatory approvals. These extended validation timelines delay purchasing decisions and slow equipment refresh cycles, particularly for small and mid-sized manufacturers.

Market Opportunities

The adoption of AI-driven inspection systems and Software-as-a-Service (SaaS) platforms presents significant growth opportunities. AI-based deep-learning models reduce false rejects, improve detection accuracy, and enable predictive analytics. Subscription-based monitoring and model updates create recurring revenue streams for vendors.

In February 2021, Syntegon Technology installed one of the first fully validated AI-driven visual inspection systems, marking a milestone in smart manufacturing. Furthermore, Industry 4.0 integration, including sensor-enabled machines and connected production lines, is accelerating digital transformation in pharmaceutical facilities.

Market Trends

Integration of sensor fusion and combination inspection systems is a prominent trend. Manufacturers are deploying unified platforms combining vision systems, X-ray inspection, metal detection, checkweighing, and leak detection to reduce production line footprints and enhance defect detection accuracy.

Additionally, the rise of personalized medicine and biopharmaceutical production is encouraging the development of specialized inspection tools tailored for sterile injectables and biologics.

Segmentation Analysis

By Component

The hardware segment dominated with an 82.19% market share in 2026, generating USD 784.1 million in revenue. Strong demand for automated visual inspection (AVI), X-ray systems, leak detection systems, and combination machines drives hardware growth.

The software segment is projected to grow at the highest CAGR of 9.6%, supported by increasing adoption of AI-based analytics, serialization systems, and track-and-trace technologies.

By Packaging Type

The injectables segment held the largest share of 43.25% in 2026 and is also the fastest-growing segment with a CAGR of 9.6%. Growing biologics and vaccine pipelines require stringent container closure integrity testing (CCIT) and particle inspection, boosting demand for advanced systems.

By Formulation

The oral segment generated USD 396.9 million in 2024, driven by high consumption of tablets and capsules. However, the parenteral segment is projected to dominate with a 41.52% share in 2026 due to rising sterile injectable production. Biologics and vaccines are expected to grow at the highest CAGR of 10.6% through 2034.

By Type

Fully automated systems generated USD 664.9 million in 2024 and remain dominant due to efficiency and reduced manual errors. This segment is also the fastest-growing, with a CAGR of 9.2%, supported by robotics integration and AI-enabled workflows.

By End User

Pharmaceutical companies led the market with USD 529.0 million in 2024, driven by modernization of legacy production lines. Biotechnology companies are expected to grow at the highest CAGR of 10.0%, fueled by expanding biologics manufacturing capacity.

Regional Outlook

Asia Pacific

Asia Pacific generated USD 379.7 million in 2025 and is projected to reach USD 416.6 million in 2026, maintaining the highest CAGR of 10.6% through 2034. China and India are key contributors, expected to generate USD 204.5 million and USD 61.9 million respectively in 2026.

North America

North America recorded USD 276.6 million in 2025 and USD 298.0 million in 2026, driven by strong R&D investments and strict regulatory compliance. The U.S. alone accounted for USD 256.9 million in 2026.

Europe

Europe generated USD 225.0 million in 2025, supported by regulatory enforcement and innovation in inspection technologies. Germany, the U.K., and Italy remain key contributors.

South America and Middle East & Africa

South America and the Middle East & Africa reached USD 80.7 million and USD 60.1 million respectively in 2025, driven by pharmaceutical production expansion and regulatory improvements.

Competitive Landscape

The market is highly fragmented, with key players including ACG Group, Antares Vision Group, Cognex Corporation, Stevanato Group, Syntegon Technology, Uhlmann Pac-Systeme, Loma Systems, Mettler-Toledo, Minebea Intec, and OPTEL Group. Strategic partnerships, AI innovation, mergers, and product launches strengthen competitive positioning.

Conclusion

The pharmaceutical inspection machines market is set for strong growth, expanding from USD 1,022.10 million in 2025 to USD 2,263.50 million by 2034, at a CAGR of 9.40%. Rising regulatory compliance requirements, growth in biologics and injectables, and increasing adoption of AI-driven inspection systems are driving market expansion. Although high capital costs and lengthy validation cycles remain challenges, digital transformation and smart manufacturing initiatives are expected to sustain long-term market growth globally.

Segmentation By Component

• Hardware
  • AVI Systems
  • X-Ray Inspection Systems
  • Leak Detection Systems
  • Metal Detectors
  • Checkweighers
  • Combination Systems
  • Others
• Software

By Packaging Type

• Injectables
• Bottles
• Blisters
• Others

By Formulation

• Oral
• Parenteral
• Biologics/Vaccines
• Others

By Type

• Fully Automated
• Semi Automated
• Manual

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• CMOs & CDMOs
• Others

By Region

• North America (By Component, Packaging Type, Formulation, Type, End User, and Country/Sub-region)
  • U.S. (By Type)
  • Canada (By Type)
  • Mexico (By Type)
• Europe ( Component, Packaging Type, Formulation, Type, End User, and Country/Sub-region)
  • U.K. (By Type)
  • Germany (By Type )
  • France (By Type )
  • Italy (By Type)
  • Rest of Europe (By Type)
• Asia Pacific (By By Component, Packaging Type, Formulation, Type, End User, and Country/Sub-region)
  • China (By Type)
  • Japan (By Type)
  • India (By Type)
  • Rest of Asia Pacific (By Type)
• South America (By Component, Packaging Type, Formulation, Type, End User, and Country/Sub-region)
  • Argentina (By Type)
  • Brazil (By Type)
  • Rest of South America (By Type)
• Middle East & Africa (By Component, Packaging Type, Formulation, Type, End User, and Country/Sub-region)
  • GCC (By Type )
  • South Africa (By Type )
• Rest of the Middle East & Africa (By Type )

Table of Content

1. Introduction

• 1.1. Definition, By Segment
• 1.2. Research Methodology/Approach
• 1.3. Data Sources

2. Executive Summary

3. Market Dynamics

• 3.1. Macro and Micro Economic Indicators
• 3.2. Drivers, Restraints, Opportunities and Trends

4. Competition Landscape

• 4.1. Business Strategies Adopted by Key Players
• 4.2. Consolidated SWOT Analysis of Key Players
• 4.3. Global Pharmaceutical Inspection Machines Key Players (Top 3 - 5) Market Share/Ranking, 2025

5. Global Pharmaceutical Inspection Machines Market Size Estimates and Forecasts, By Segments, 2021-2034

• 5.1. Key Findings
• 5.2. By Component (USD)
  • 5.2.1. Hardware
    • 5.2.1.1. AVI Systems
    • 5.2.1.2. X-Ray Inspection Systems
    • 5.2.1.3. Leak Detection Systems
    • 5.2.1.4. Metal Detectors
    • 5.2.1.5. Checkweighers
    • 5.2.1.6. Combination Systems
    • 5.2.1.7. Others
  • 5.2.2. Software
• 5.3. By Packaging Type (USD)
  • 5.3.1. Injectables
  • 5.3.2. Bottles
  • 5.3.3. Blisters
  • 5.3.4. Others
• 5.4. By Formulation (USD)
  • 5.4.1. Oral
  • 5.4.2. Parenteral
  • 5.4.3. Biologics/Vaccines
  • 5.4.4. Others
• 5.5. By Type (USD)
  • 5.5.1. Fully Automated
  • 5.5.2. Semi Automated
  • 5.5.3. Manual
• 5.6. By End User (USD)
  • 5.6.1. Pharmaceutical Companies
  • 5.6.2. Biotechnology Companies
  • 5.6.3. CMOs & CDMOs
  • 5.6.4. Others
• 5.7. By Region (USD)
  • 5.7.1. North America
  • 5.7.2. South America
  • 5.7.3. Europe
  • 5.7.4. Asia Pacific
  • 5.7.5. Middle East & Africa

6. North America Pharmaceutical Inspection Machines Market Size Estimates and Forecasts, By Segments, 2021-2034

• 6.1. Key Findings
• 6.2. By Component (USD)
  • 6.2.1. Hardware
    • 6.2.1.1. AVI Systems
    • 6.2.1.2. X-Ray Inspection Systems
    • 6.2.1.3. Leak Detection Systems
    • 6.2.1.4. Metal Detectors
    • 6.2.1.5. Checkweighers
    • 6.2.1.6. Combination Systems
    • 6.2.1.7. Others
  • 6.2.2. Software
• 6.3. By Packaging Type (USD)
  • 6.3.1. Injectables
  • 6.3.2. Bottles
  • 6.3.3. Blisters
  • 6.3.4. Others
• 6.4. By Formulation (USD)
  • 6.4.1. Oral
  • 6.4.2. Parenteral
  • 6.4.3. Biologics/Vaccines
  • 6.4.4. Others
• 6.5. By Type (USD)
  • 6.5.1. Fully Automated
  • 6.5.2. Semi Automated
  • 6.5.3. Manual
• 6.6. By End User (USD)
  • 6.6.1. Pharmaceutical Companies
  • 6.6.2. Biotechnology Companies
  • 6.6.3. CMOs & CDMOs
  • 6.6.4. Others
• 6.7. By Country (USD)
  • 6.7.1. U.S.
    • 6.7.1.1. By Type (USD)
  • 6.7.2. Canada
    • 6.7.2.1. By Type (USD)
  • 6.7.3. Mexico
    • 6.7.3.1. By Type (USD)

7. South America Pharmaceutical Inspection Machines Market Size Estimates and Forecasts, By Segments, 2021-2034

• 7.1. Key Findings
• 7.2. By Component (USD)
  • 7.2.1. Hardware
    • 7.2.1.1. AVI Systems
    • 7.2.1.2. X-Ray Inspection Systems
    • 7.2.1.3. Leak Detection Systems
    • 7.2.1.4. Metal Detectors
    • 7.2.1.5. Checkweighers
    • 7.2.1.6. Combination Systems
    • 7.2.1.7. Others
  • 7.2.2. Software
• 7.3. By Packaging Type (USD)
  • 7.3.1. Injectables
  • 7.3.2. Bottles
  • 7.3.3. Blisters
  • 7.3.4. Others
• 7.4. By Formulation (USD)
  • 7.4.1. Oral
  • 7.4.2. Parenteral
  • 7.4.3. Biologics/Vaccines
  • 7.4.4. Others
• 7.5. By Type (USD)
  • 7.5.1. Fully Automated
  • 7.5.2. Semi Automated
  • 7.5.3. Manual
• 7.6. By End User (USD)
  • 7.6.1. Pharmaceutical Companies
  • 7.6.2. Biotechnology Companies
  • 7.6.3. CMOs & CDMOs
  • 7.6.4. Others
• 7.7. By Country (USD)
  • 7.7.1. Brazil
    • 7.7.1.1. By Type (USD)
  • 7.7.2. Argentina
    • 7.7.2.1. By Type (USD)
  • 7.7.3. Rest of South America

8. Europe Pharmaceutical Inspection Machines Market Size Estimates and Forecasts, By Segments, 2021-2034

• 8.1. Key Findings
• 8.2. By Component (USD)
  • 8.2.1. Hardware
    • 8.2.1.1. AVI Systems
    • 8.2.1.2. X-Ray Inspection Systems
    • 8.2.1.3. Leak Detection Systems
    • 8.2.1.4. Metal Detectors
    • 8.2.1.5. Checkweighers
    • 8.2.1.6. Combination Systems
    • 8.2.1.7. Others
  • 8.2.2. Software
• 8.3. By Packaging Type (USD)
  • 8.3.1. Injectables
  • 8.3.2. Bottles
  • 8.3.3. Blisters
  • 8.3.4. Others
• 8.4. By Formulation (USD)
  • 8.4.1. Oral
  • 8.4.2. Parenteral
  • 8.4.3. Biologics/Vaccines
  • 8.4.4. Others
• 8.5. By Type (USD)
  • 8.5.1. Fully Automated
  • 8.5.2. Semi Automated
  • 8.5.3. Manual
• 8.6. By End User (USD)
  • 8.6.1. Pharmaceutical Companies
  • 8.6.2. Biotechnology Companies
  • 8.6.3. CMOs & CDMOs
  • 8.6.4. Others
• 8.7. By Country (USD)
  • 8.7.1. Germany
    • 8.7.1.1. By Type (USD)
  • 8.7.2. U.K.
    • 8.7.2.1. By Type (USD)
  • 8.7.3. France
    • 8.7.3.1. By Type (USD)
  • 8.7.4. Italy
    • 8.7.4.1. By Type (USD)
  • 8.7.5. Rest of Europe

9. Asia Pacific Pharmaceutical Inspection Machines Market Size Estimates and Forecasts, By Segments, 2021-2034

• 9.1. Key Findings
• 9.2. By Component (USD)
  • 9.2.1. Hardware
    • 9.2.1.1. AVI Systems
    • 9.2.1.2. X-Ray Inspection Systems
    • 9.2.1.3. Leak Detection Systems
    • 9.2.1.4. Metal Detectors
    • 9.2.1.5. Checkweighers
    • 9.2.1.6. Combination Systems
    • 9.2.1.7. Others
  • 9.2.2. Software
• 9.3. By Packaging Type (USD)
  • 9.3.1. Injectables
  • 9.3.2. Bottles
  • 9.3.3. Blisters
  • 9.3.4. Others
• 9.4. By Formulation (USD)
  • 9.4.1. Oral
  • 9.4.2. Parenteral
  • 9.4.3. Biologics/Vaccines
  • 9.4.4. Others
• 9.5. By Type (USD)
  • 9.5.1. Fully Automated
  • 9.5.2. Semi Automated
  • 9.5.3. Manual
• 9.6. By End User (USD)
  • 9.6.1. Pharmaceutical Companies
  • 9.6.2. Biotechnology Companies
  • 9.6.3. CMOs & CDMOs
  • 9.6.4. Others
• 9.7. By Country (USD)
  • 9.7.1. China
    • 9.7.1.1. By Type (USD)
  • 9.7.2. Japan
    • 9.7.2.1. By Type (USD)
  • 9.7.3. South Korea
    • 9.7.3.1. By Type (USD)
  • 9.7.4. India
    • 9.7.4.1. By Type (USD)
  • 9.7.5. Rest of Asia Pacific

10. Middle East & Africa Pharmaceutical Inspection Machines Market Size Estimates and Forecasts, By Segments, 2021-2034

• 10.1. Key Findings
• 10.2. By Component (USD)
  • 10.2.1. Hardware
    • 10.2.1.1. AVI Systems
    • 10.2.1.2. X-Ray Inspection Systems
    • 10.2.1.3. Leak Detection Systems
    • 10.2.1.4. Metal Detectors
    • 10.2.1.5. Checkweighers
    • 10.2.1.6. Combination Systems
    • 10.2.1.7. Others
  • 10.2.2. Software
• 10.3. By Packaging Type (USD)
  • 10.3.1. Injectables
  • 10.3.2. Bottles
  • 10.3.3. Blisters
  • 10.3.4. Others
• 10.4. By Formulation (USD)
  • 10.4.1. Oral
  • 10.4.2. Parenteral
  • 10.4.3. Biologics/Vaccines
  • 10.4.4. Others
• 10.5. By Type (USD)
  • 10.5.1. Fully Automated
  • 10.5.2. Semi Automated
  • 10.5.3. Manual
• 10.6. By End User (USD)
  • 10.6.1. Pharmaceutical Companies
  • 10.6.2. Biotechnology Companies
  • 10.6.3. CMOs & CDMOs
  • 10.6.4. Others
• 10.7. By Country (USD)
  • 10.7.1. GCC
    • 10.7.1.1. By Type (USD)
  • 10.7.2. South Africa
    • 10.7.2.1. By Type (USD)
  • 10.7.3. Rest of MEA

11. Company Profiles for Top 10 Players (Based on data availability in public domain and/or on paid databases)

• 11.1. ACG Group
  • 11.1.1. Overview
    • 11.1.1.1. Key Management
    • 11.1.1.2. Headquarters
    • 11.1.1.3. Offerings/Business Segments
  • 11.1.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.1.2.1. Employee Size
    • 11.1.2.2. Past and Current Revenue
    • 11.1.2.3. Geographical Share
    • 11.1.2.4. Business Segment Share
    • 11.1.2.5. Recent Developments
• 11.2. Antares Vision Group
  • 11.2.1. Overview
    • 11.2.1.1. Key Management
    • 11.2.1.2. Headquarters
    • 11.2.1.3. Offerings/Business Segments
  • 11.2.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.2.2.1. Employee Size
    • 11.2.2.2. Past and Current Revenue
    • 11.2.2.3. Geographical Share
    • 11.2.2.4. Business Segment Share
    • 11.2.2.5. Recent Developments
• 11.3. Cognex Corporation
  • 11.3.1. Overview
    • 11.3.1.1. Key Management
    • 11.3.1.2. Headquarters
    • 11.3.1.3. Offerings/Business Segments
  • 11.3.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.3.2.1. Employee Size
    • 11.3.2.2. Past and Current Revenue
    • 11.3.2.3. Geographical Share
    • 11.3.2.4. Business Segment Share
    • 11.3.2.5. Recent Developments
• 11.4. Keyence Corporation
  • 11.4.1. Overview
    • 11.4.1.1. Key Management
    • 11.4.1.2. Headquarters
    • 11.4.1.3. Offerings/Business Segments
  • 11.4.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.4.2.1. Employee Size
    • 11.4.2.2. Past and Current Revenue
    • 11.4.2.3. Geographical Share
    • 11.4.2.4. Business Segment Share
    • 11.4.2.5. Recent Developments
• 11.5. Mettler-Toledo
  • 11.5.1. Overview
    • 11.5.1.1. Key Management
    • 11.5.1.2. Headquarters
    • 11.5.1.3. Offerings/Business Segments
  • 11.5.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.5.2.1. Employee Size
    • 11.5.2.2. Past and Current Revenue
    • 11.5.2.3. Geographical Share
    • 11.5.2.4. Business Segment Share
    • 11.5.2.5. Recent Developments
• 11.6. Minebea Intec
  • 11.6.1. Overview
    • 11.6.1.1. Key Management
    • 11.6.1.2. Headquarters
    • 11.6.1.3. Offerings/Business Segments
  • 11.6.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.6.2.1. Employee Size
    • 11.6.2.2. Past and Current Revenue
    • 11.6.2.3. Geographical Share
    • 11.6.2.4. Business Segment Share
    • 11.6.2.5. Recent Developments
• 11.7. OPTEL Group
  • 11.7.1. Overview
    • 11.7.1.1. Key Management
    • 11.7.1.2. Headquarters
    • 11.7.1.3. Offerings/Business Segments
  • 11.7.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.7.2.1. Employee Size
    • 11.7.2.2. Past and Current Revenue
    • 11.7.2.3. Geographical Share
    • 11.7.2.4. Business Segment Share
    • 11.7.2.5. Recent Developments
• 11.8. Stevanato Group
  • 11.8.1. Overview
    • 11.8.1.1. Key Management
    • 11.8.1.2. Headquarters
    • 11.8.1.3. Offerings/Business Segments
  • 11.8.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.8.2.1. Employee Size
    • 11.8.2.2. Past and Current Revenue
    • 11.8.2.3. Geographical Share
    • 11.8.2.4. Business Segment Share
    • 11.8.2.5. Recent Developments
• 11.9. Syntegon Technology
  • 11.9.1. Overview
    • 11.9.1.1. Key Management
    • 11.9.1.2. Headquarters
    • 11.9.1.3. Offerings/Business Segments
  • 11.9.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.9.2.1. Employee Size
    • 11.9.2.2. Past and Current Revenue
    • 11.9.2.3. Geographical Share
    • 11.9.2.4. Business Segment Share
    • 11.9.2.5. Recent Developments
• 11.10. Uhlmann Pac-Systeme
  • 11.10.1. Overview
    • 11.10.1.1. Key Management
    • 11.10.1.2. Headquarters
    • 11.10.1.3. Offerings/Business Segments
  • 11.10.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.10.2.1. Employee Size
    • 11.10.2.2. Past and Current Revenue
    • 11.10.2.3. Geographical Share
    • 11.10.2.4. Business Segment Share
    • 11.10.2.5. Recent Developments

12. Key Takeaways